文献速递前列腺癌

低基线PSA的转移性去势抵抗性前列腺癌化疗初治患者:恩扎卢胺与安慰剂的临床结局

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.
PubMed 文献 · J Urol · 2017-07-20

基于PREVAIL研究的事后探索性分析,评估低基线PSA(<10 ng/ml)的转移性去势抵抗性前列腺癌化疗初治患者接受恩扎卢胺或安慰剂的结局。1717例中242例(14.1%)低基线PSA,恩扎卢胺较安慰剂降低影像学进展风险(HR 0.20,95%CI 0.10-0.42),不受肿瘤负荷影响,两组中位总生存均未达到。

要点

  • 低基线PSA定义为<10 ng/ml,PREVAIL中242/1717例(14.1%)符合。
  • 恩扎卢胺较安慰剂降低影像学进展风险:HR 0.20(95%CI 0.10-0.42)。
  • 高瘤负荷HR 0.17(95%CI 0.06-0.51),低瘤负荷HR 0.25(95%CI 0.09-0.70)。

核心结论

  • 化疗初治的转移性去势抵抗性前列腺癌且低基线PSA患者,无论疾病负荷如何,可能从恩扎卢胺获益。
  • 作者认为靶向雄激素受体信号通路是类似患者的治疗选择。

研究设计与样本

  • PREVAIL研究的事后探索性分析,低基线PSA定义为<10 ng/ml,按高瘤负荷(>4处骨转移和/或内脏转移)与低瘤负荷(≤4处骨转移且无内脏转移)分层。

主要发现

  • 1717例入组患者中242例(14.1%)低基线PSA,其中110例高瘤负荷。
  • 恩扎卢胺较安慰剂降低低基线PSA患者影像学进展风险(HR 0.20,95%CI 0.10-0.42)。
  • 高瘤负荷患者HR 0.17(95%CI 0.06-0.51),低瘤负荷患者HR 0.25(95%CI 0.09-0.70)。
  • 低基线PSA患者两个治疗组的中位总生存均未达到。

关键数值与推荐

  • 低基线PSA:<10 ng/ml。
  • 高瘤负荷:>4处骨转移和/或内脏转移;低瘤负荷:≤4处骨转移且无内脏转移。
  • 恩扎卢胺每日一次口服。

临床怎么用

  • 作者认为,化疗初治的转移性去势抵抗性前列腺癌且低基线PSA患者,无论疾病负荷如何,可能从恩扎卢胺获益,靶向雄激素受体信号通路是治疗选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Metastatic castration resistant prostate cancer with low baseline prostate specific antigen represents an early stage in the natural history of castration resistant prostate cancer progression (low volume disease), low prostate specific antigen producing disease or disease that is less dependent on androgen receptor biology (high volume disease). We analyzed outcomes in men with low prostate specific antigen and a high disease burden who received the oral androgen receptor inhibitor enzalutamide in the PREVAIL (Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer) study. MATERIALS AND METHODS: In this exploratory analysis low baseline prostate specific antigen was defined as less than 10 ng/ml. Post hoc analyses included radiographic progression-free and overall survival in the once daily enzalutamide and placebo arms. Patients were stratified post hoc by high volume disease, defined as more than 4 bone metastases and/or visceral disease, and low volume disease, defined as 4 or fewer bone metastases with no visceral disease. RESULTS: Of 1,717 patients enrolled in PREVAIL 242 (14.1%) had low baseline prostate specific antigen, including 110 with high volume disease. Enzalutamide decreased the risk of radiographic progression relative to placebo in patients with low baseline prostate specific antigen (HR 0.20, 95% CI 0.10-0.42). This decrease was irrespective of tumor burden (high volume disease HR 0.17, 95% CI 0.06-0.51 and low volume disease HR 0.25, 95% CI 0.09-0.70). Median overall survival was not reached in patients with low baseline prostate specific antigen in either treatment arm. CONCLUSIONS: Chemotherapy naïve men with metastatic castration resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden may benefit from enzalutamide. This indicates that targeting the androgen receptor signaling pathway is a therapeutic option in similar patients.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Taplin ME, Armstrong AJ, Lin P, et al. Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. J Urol. 2017. PMID: 28736322. doi:10.1016/j.juro.2017.07.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。